MiMedx Q3 swings to $8.68 million net loss year-over-year; Q3 net sales fall 45% to $62.28 million year-over-year

• MiMedx swung to a third-quarter 2026 net loss of $8.68 million from year-earlier net income of $16.75 million.
• Net sales fell 45% year-over-year to $62.28 million, with Wound performance hurt by Medicare reimbursement changes.
• Surgical net sales rose 9% year-over-year to $39.96 million, while Wound net sales dropped 71% to $22.32 million.
• A patent license agreement with a wound care competitor will bring in $25 million through five equal installments.
• The 2026 net sales outlook now stands at $250 million to $260 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MiMedx Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610281603PRIMZONEFULLFEED9855454) on October 28, 2026, and is solely responsible for the information contained therein.